PafosPharma is developing new medications for the treatment of ulcerative colitis by reducing inflammatory conditions and controlling its symptoms (inducing remission), reducing frequency of flareups.
IBD Irritable Bowel Disease
Addiction
PafosPharma’s proprietary technologies and experience give us an advantage in developing innovative medications to help with addiction. In the United States alone it is estimated that over 20 million people over the age of 12 have an addiction (these numbers exclude tobacco addiction). With approximately 100 people dying every day from a drug overdose and over 5 million visits to the ER yearly the cost to society is high.
Newsworthy/Upcoming Events
The 5th Annual Chemistry and Pharmacology of Drug Abuse (CPDA) meeting was held in Boston, MA, in August 2020. For more information and to view the program click below. Watch our website for the dates and location of next year’s meeting or click the link below.
New Publications
-
- Crystal Structures of Agonist-bound Human Cannabinoid Receptor CB1
- Crystal Structure of the Human Cannabinoid Receptor CB2
- Crystal Structure of the Human Cannabinoid Receptor CB1
PTSD
PafosPharma is testing a new medication that has the potential to help returning veterans and others suffering from PTSD and improve their sleep condition.
Pain
Neuropathic pain affects over 1.5% of the US population. This included pain from diabetic and herpetic neuropathies, post therapeutic neuralgia, back pain and nerve injury due to trauma, surgery and amputation. Peripheral pain is the largest pain indication which includes pain from osteoarthritis, cancer surgery and low back ailments. The current drugs available are effective but have severely limiting side effects.
PafosPharma has developed approaches that reduce neuropathic and peripheral pain by selectively activating the CB2 cannabinoid system.
Inflammatory Response
PafosPharma is developing efficacious and safe medications that act through the PPAR alpha system by activating an endogenously produced neurotransmitter. This approach lacks the ill effects that occur when PPAR alpha is activated from directly acting drugs.
PafosPharma and MAKScientific are Sister Companies
Founded by Alexandros Makriyannis, PafosPharma and its sister company MAKScientific were based on research by the founder. To find out more about MAKScientific, please press the button below.
